Biocytogen-B Shares Surge Over 5% in Morning Session Following Formal Strategic Partnership Agreement

Deep News04-02

Biocytogen-B (02315) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 5.29%, trading at HK$62.70, with a turnover of HK$56.9547 million.

Sihuan Pharmaceutical and Biocytogen have officially signed a strategic cooperation agreement. The collaboration will leverage Biocytogen's leading fully human antibody development platform, combined with Sihuan Pharmaceutical's extensive experience in drug development, production, and commercialization. The partnership will focus on innovative drug research and development across multiple disease areas, including weight loss, aiming to achieve complementary advantages and resource synergy, and to establish a long-term, stable cooperative relationship. The first project under this strategic cooperation will center on the company's next-generation innovative weight-loss drug currently under development.

Sihuan Pharmaceutical highly recognizes the technical capabilities of Biocytogen's platform. In this collaboration, Biocytogen will utilize its comprehensive advantages, including its self-developed model animal and efficacy platform, fully human antibody discovery platform, and AI-driven antibody drug R&D platform, to provide strong support for the subsequent cooperation. By integrating the capabilities of both parties in innovative research and industrial transformation, the partnership is expected to further enhance the efficiency of innovative drug development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199722588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199722588","market":"us","top_or_hot":-1,"title":"Biocytogen-B Shares Surge Over 5% in Morning Session Following Formal Strategic Partnership Agreement","media":"Deep News","content":"<p>Biocytogen-B (02315) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 5.29%, trading at HK$62.70, with a turnover of HK$56.9547 million.</p>\n<p>Sihuan Pharmaceutical and Biocytogen have officially signed a strategic cooperation agreement. The collaboration will leverage Biocytogen's leading fully human antibody development platform, combined with Sihuan Pharmaceutical's extensive experience in drug development, production, and commercialization. The partnership will focus on innovative drug research and development across multiple disease areas, including weight loss, aiming to achieve complementary advantages and resource synergy, and to establish a long-term, stable cooperative relationship. The first project under this strategic cooperation will center on the company's next-generation innovative weight-loss drug currently under development.</p>\n<p>Sihuan Pharmaceutical highly recognizes the technical capabilities of Biocytogen's platform. In this collaboration, Biocytogen will utilize its comprehensive advantages, including its self-developed model animal and efficacy platform, fully human antibody discovery platform, and AI-driven antibody drug R&D platform, to provide strong support for the subsequent cooperation. By integrating the capabilities of both parties in innovative research and industrial transformation, the partnership is expected to further enhance the efficiency of innovative drug development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen-B Shares Surge Over 5% in Morning Session Following Formal Strategic Partnership Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen-B Shares Surge Over 5% in Morning Session Following Formal Strategic Partnership Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-02 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen-B (02315) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 5.29%, trading at HK$62.70, with a turnover of HK$56.9547 million.</p>\n<p>Sihuan Pharmaceutical and Biocytogen have officially signed a strategic cooperation agreement. The collaboration will leverage Biocytogen's leading fully human antibody development platform, combined with Sihuan Pharmaceutical's extensive experience in drug development, production, and commercialization. The partnership will focus on innovative drug research and development across multiple disease areas, including weight loss, aiming to achieve complementary advantages and resource synergy, and to establish a long-term, stable cooperative relationship. The first project under this strategic cooperation will center on the company's next-generation innovative weight-loss drug currently under development.</p>\n<p>Sihuan Pharmaceutical highly recognizes the technical capabilities of Biocytogen's platform. In this collaboration, Biocytogen will utilize its comprehensive advantages, including its self-developed model animal and efficacy platform, fully human antibody discovery platform, and AI-driven antibody drug R&D platform, to provide strong support for the subsequent cooperation. By integrating the capabilities of both parties in innovative research and industrial transformation, the partnership is expected to further enhance the efficiency of innovative drug development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1199722588","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199722588","pubTimestamp":1775101239,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Biocytogen-B (02315) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 5.29%, trading at HK$62.70, with a turnover of HK$56.9547 million. Sihuan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","02315":"百奥赛图-B","BK1161":"生物科技"},"translate_title":"签署正式战略合作协议后，百奥赛图-B股价早盘飙升逾5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1},"content_text":"Biocytogen-B (02315) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 5.29%, trading at HK$62.70, with a turnover of HK$56.9547 million.\nSihuan Pharmaceutical and Biocytogen have officially signed a strategic cooperation agreement. The collaboration will leverage Biocytogen's leading fully human antibody development platform, combined with Sihuan Pharmaceutical's extensive experience in drug development, production, and commercialization. The partnership will focus on innovative drug research and development across multiple disease areas, including weight loss, aiming to achieve complementary advantages and resource synergy, and to establish a long-term, stable cooperative relationship. The first project under this strategic cooperation will center on the company's next-generation innovative weight-loss drug currently under development.\nSihuan Pharmaceutical highly recognizes the technical capabilities of Biocytogen's platform. In this collaboration, Biocytogen will utilize its comprehensive advantages, including its self-developed model animal and efficacy platform, fully human antibody discovery platform, and AI-driven antibody drug R&D platform, to provide strong support for the subsequent cooperation. By integrating the capabilities of both parties in innovative research and industrial transformation, the partnership is expected to further enhance the efficiency of innovative drug development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199722588","isCrawlerRequest":true}